Comparison of Endocrine Therapies in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer: A Network Meta-Analysis

Liu, Siqi; Sun, Xiaohong; Xu, Xiaohui; Lin, Fang‐Yue

doi:10.4048/jbc.2020.23.e55

Cited by 2 publications

(5 citation statements)

References 69 publications

(77 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Выживаемость без прогрессирования по материалам рандомизированных клинических исследований и исследований на данных реальной клинической практики [8-10, 15-21, 34] Table 3. Progression-free survival demonstrated by randomized controlled trials and studies based on routine clinical practice практики [8-10, 15-21, 34] [15,16,[22][23][24][31][32][33] Table 4. Comparison of overall survival [15,16,[22][23][24][31][32][33] Авторы исследования…”

Section: опухоли женской репродуктивной системы Tumors Of Female Repr...unclassified

“…Progression-free survival demonstrated by randomized controlled trials and studies based on routine clinical practice практики [8-10, 15-21, 34] [15,16,[22][23][24][31][32][33] Table 4. Comparison of overall survival [15,16,[22][23][24][31][32][33] Авторы исследования…”

Section: опухоли женской репродуктивной системы Tumors Of Female Repr...mentioning

confidence: 99%

“…Рибоциклиб + ГТ (n = 54, в том числе 34 в комбинации с ИА) Абемациклиб + ГТ (n = 56, в том числе 29 в комбинации с ИА) Palbociclib + HT (n = 96, including 53 in combination with AI) Ribociclib + HT (n = 54, including 34 in combination with AI) Abemaciclib + HT (n = 56, including 29 in combination with AI) Палбоциклиб + ГТ (n = 79, в том числе 37 -в составе 1-й линии, 34 -в комбинации с ИА) Рибоциклиб + ГТ (n = 42, в том числе 33 -в составе 1-й линии, 31 -в комбинации с ИА) Абемациклиб + ГТ (n = 21, в том числе 9 -в составе 1-й линии, 9 -в комбинации с ИА) Palbociclib + HT (n = 79, including 37 as first-line therapy, 34 in combination with AI) Ribociclib + HT (n = 42 including 33 as first-line therapy, 31 in combination with AI) Abemaciclib + HT (n = 21, including 9 as first-line therapy, 9 in combination with AI) Палбоциклиб + ГТ (n = 33, в том числе 6 -в составе 1-й линии, 8 -в комбинации с ИА) Рибоциклиб + ГТ (n = 28, в том числе 19 -в составе 1-й линии, 25 -в комбинации с ИА) Palbociclib + HT (n = 33, including 6 as first-line therapy, 8 in combination with AI) Ribociclib + HT (n = 28, including 19 as first-line therapy, 25 in combination with AI)No Таблица 1. Общая характеристика отобранных исследований[15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33] …”

unclassified

“…General characteristics of the studies included[15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33] …”

mentioning

confidence: 99%

“…Результаты сравнительного анализа выживаемости без прогрессирования[15][16][17][22][23][24][25][26][27][28][29][30][31][32][33] …”

unclassified

See 4 more Smart Citations

Effectiveness of cyclin-dependent kinase 4 and 6 inhibitors for the treatment of hormonesensitive HER2-negative metastatic breast cancer in first-line therapy: A systematic literature review

Avxentyev,

Andreyashkina,

Artamonova

et al. 2024

Opuholi ženskoj reproduktivnoj sistemy

View full text Add to dashboard Cite

At present, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors such as palbociclib, ribociclib, and abemaciclib are widely used for the first-line treatment of locally advanced or metastatic breast cancer. However, direct comparisons of these treatment options in randomized studies have not been conducted.Aim of the work is to gather and analyze published data on the comparative effectiveness of CDK4/6 inhibitors in combination with aromatase inhibitors in postmenopausal patients with HR+/HER2– locally advanced or metastatic breast cancer. A systematic review of publications presenting results from original studies on the impact of CDK4/6 inhibitor therapy in combination with aromatase inhibitors on the survival of patients was performed. Nineteen studies with original data on progression-free survival and overall survival were identified. None of the studies found significant differences between different CDK4/6 inhibitors and aromatase inhibitors in terms of progression-free survival. A statistically significant superiority of ribociclib over palbociclib in terms of overall survival was observed in a single matching-adjusted indirect comparison, while seven other studies of various types (real-world data studies, matching-adjusted indirect comparisons, and meta-analyses) did not find significant differences between the investigated drugs in terms of overall survival.Currently, there is no compelling evidence of the superiority of one CDK4/6 inhibitor over others. The decision on the preference for a specific drug within the class can only be made after conducting direct randomized comparison trials, or accumulating sufficient real-world data on the use of palbociclib, ribociclib, and abemaciclib.

show abstract

Section: опухоли женской репродуктивной системы Tumors Of Female Repr...unclassified

Section: опухоли женской репродуктивной системы Tumors Of Female Repr...mentioning

confidence: 99%

unclassified

“…General characteristics of the studies included[15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33] …”

mentioning

confidence: 99%

unclassified

See 3 more Smart Citations

Effectiveness of cyclin-dependent kinase 4 and 6 inhibitors for the treatment of hormonesensitive HER2-negative metastatic breast cancer in first-line therapy: A systematic literature review

Avxentyev,

Andreyashkina,

Artamonova

et al. 2024

Opuholi ženskoj reproduktivnoj sistemy

View full text Add to dashboard Cite

show abstract

Second-line Endocrine Therapy of Hormone Receptor-positive/HER2- negative Advanced Breast Cancer: A Systematic Review and Network Meta-analysis

Wang

Shen

et al. 2023

CCDT

View full text Add to dashboard Cite

Background: The optimal second-line therapy for hormone receptor–positive (HR+)/ human epidermal growth factor receptor 2 negative (HER2−) advanced or metastatic breast cancer is yet to be established. Therefore, we conducted a network meta-analysis (NMA) of marketed drugs to compare their efficacy. Methods: We searched the literature in PubMed, Embase, Web of Science databases, and the main international conferences in the past 5 years to find phase III clinical trials on drugs available in the market. Network meta-analysis of progression-free survival (PFS), overall survival (OS), and the objective response rate (ORR) was performed using R software. The efficiency of treatment options was compared using hazard ratios and 95% credibility intervals. Results: Overall, 12 studies with 6120 patients were included in the analysis. In an indirect comparison of the five regimens, cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) plus 500 mg fulvestrant (Ful500) gave the best PFS results; palbociclib ranked first with a surface under the cumulative ranking (SUCRA) of 94.99%, followed by mammalian target of rapamycin inhibitor (mTORi) plus everolimus (SUCRA=73.07%), phosphoinositide 3–kinase inhibitor (PI3Ki) plus Ful500 (SUCRA=66.73%), Ful500 alone (SUCRA=44.55%), and histone deacetylase inhibitor (HDACi) plus exemestane (SUCRA=43.49%). However, no significant difference was found in the PFS rates of CDK4/6i, mTORi, and PI3Ki. For OS, CDK4/6i plus Ful500 ranked first; the SUCRA of ribociclib, abemaciclib, and palbociclib were 86.20%, 83.98%, and 78.52%, respectively. Alpelisib plus Ful500 (SUCRA=66.91%) ranked second but was not statistically different from CDK4/6i. The mTORi plus everolimus group had the best ORR (SUCRA=88.73%). In terms of safety, 81.56% of patients in the tucidinostat plus exemestane regimen developed neutropenia, suggesting strong hematological toxicity; 13.40% of patients developed grade 3–4 diarrhea after using abemaciclib plus Ful500. Conclusion: For second-line endocrine therapy in HR+/HER2− advanced/metastatic breast cancer, CDK4/6i is a better choice than mTORi, PI3Ki, HDACi, and Ful; it shows good PFS and OS outcomes and a low probability for serious adverse events.

show abstract

Comparison of Endocrine Therapies in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer: A Network Meta-Analysis

Cited by 2 publications

References 69 publications

Effectiveness of cyclin-dependent kinase 4 and 6 inhibitors for the treatment of hormonesensitive HER2-negative metastatic breast cancer in first-line therapy: A systematic literature review

Effectiveness of cyclin-dependent kinase 4 and 6 inhibitors for the treatment of hormonesensitive HER2-negative metastatic breast cancer in first-line therapy: A systematic literature review

Second-line Endocrine Therapy of Hormone Receptor-positive/HER2- negative Advanced Breast Cancer: A Systematic Review and Network Meta-analysis

Contact Info

Product

Resources

About